Marten Heeringa, MSc; Eugene P. van Puijenbroek, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Heeringa M, van Puijenbroek EP. Reversible Dysgeusia Attributed to Losartan. Ann Intern Med. 1998;129:72. doi: 10.7326/0003-4819-129-1-199807010-00023
Download citation file:
Published: Ann Intern Med. 1998;129(1):72.
TO THE EDITOR:
Like angiotensin-converting enzyme (ACE) inhibitors, losartan interferes with the renin-angiotensin-aldosterone system by decreasing angiotensin II-mediated effects. Although losartan and ACE inhibitors have similar therapeutic potency, losartan reportedly has fewer adverse effects because of selective antagonism of angiotensin I receptors . Schlienger and colleagues  recently described a patient in whom losartan induced reversible ageusia; we present two similar reports.
A 49-year-old woman had been using enalapril (10 mg/d) for the treatment of hypertension. Because of fatigue, therapy was changed to losartan (50 mg/d). One week after the initiation of therapy, the patient reported a persistent metallic taste, a tickling cough, and intestinal symptoms. After discontinuation of losartan therapy, symptoms disappeared. Concomitant medications were carbaspirin calcium (38 mg/d), cetirizine (10 mg/d), and ranitidine (150 mg three times daily).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only